| Literature DB >> 30398294 |
Zobair Younossi1,2, Georgios Papatheodoridis3, Patrice Cacoub4,5, Francesco Negro6, Heiner Wedemeyer7, Linda Henry8, Angelos Hatzakis9,10.
Abstract
Treatment of hepatitis C virus (HCV) infection has been revolutionized with the introduction of pangenotypic, interferon- and ribavirin-free regimens associated with high cure rates and a low side effect profile. Additionally, there is evidence that HCV cure reduces HCV complications, improves patient-reported outcomes and is cost-saving in most western countries in the long term. This is a review of the comprehensive burden of HCV and the value of eliminating HCV infection. With the introduction of the interferon-free all-oral, once a day pill treatment regimen for the cure of HCV, the potential to eliminate HCV by 2030 has become a possibility for some regions of the world. Nevertheless, there are barriers to screening, linkage to care, and treatment in many countries that must be overcome in order to reach this goal. In conclusion, globally, work must continue to ensure national policies are in place to support screening, linkage to care and affordable treatment in order to eliminate HCV.Entities:
Keywords: clinical; economics; extrahepatic manifestations; patient-reported outcomes
Mesh:
Substances:
Year: 2018 PMID: 30398294 DOI: 10.1111/jvh.13005
Source DB: PubMed Journal: J Viral Hepat ISSN: 1352-0504 Impact factor: 3.728